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ABSTRACT 
 
Background: In a previous study, it was shown that melanoma patients have a greater 
incidence of glioma as compared to the general population in United States. Because 
glioma and melanoma do not have common environmental risk factors, this observation 
suggests a common genetic predisposition shared by glioma and melanoma that maybe 
used to lead future research of the specific genes and drug targets for both malignancies. 
However, this observation has to be confirmed in other populations. The aim of this study 
was to investigate the association between melanoma and glioma in Taiwanese population. 
 
Methods: We used claim data of Taiwan’s National Health Insurance Research Database 
(NHIRD) from year 1998 to 2010. The study population included 1,000,000 randomly 
selected men and women ages 20 and older from the NHIRD database. Glioma was defined 
by ICD-9-CM codes 191, 192.0-192.3, 192.8, 192.9, 225 and 237.5. Melanoma was 
defined by ICD-9-CM codes 172, 173, 190.0, 190.9, 192.1, 216.X (X=0, 3-7, 9), 224, 223.2, 
235.1, 235.2, 237.6, 238.2, 238.3, 238.8. We excluded participants under ages 20 at 1998 
and unknown gender (n=324,879). Cox's proportional hazard regression analysis was 
conducted to estimate the association between the history of melanoma on glioma risk.   
 
Main results: The hazard ratio of developing glioma was significantly higher in patients 
with melanoma than in those without melanoma (hazard ratio (HR) = 6.18; 95% confidence 
interval (CI) = 5.57-6.85). The hazard ratio for developing glioma was lower in male 
patients than in female patients, with the hazard ratio of 0.77 (95% CI = 0.71-0.84), 
adjusted for melanoma and age. The hazard ratio increased with age peaking at age group 
age from 60 to 69 and decrease after 70 years and older. 
 
Conclusion: The present study showed that Taiwanese patients with melanoma are at a 
higher risk of developing glioma. The exact underlying etiologies require further 
investigation. 
 
 
Keywords: Epidemiology, Melanoma, Glioma 
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 CHAPTER I 
INTRODUCTION  
1.1 Background and Purpose of the Study 
Gliomas are the tumors that arise from the glial cells of the brain, and constitute a 
large portion of all malignant central nervous system (CNS) tumors in the United States 
(77%), and approximately 91% of CNS tumors in Taiwan 2013 (Chien et al., 2016; 
Scarbrough, Akushevich, Wrensch, & Il'yasova, 2014; Schwartzbaum, Fisher, Aldape, & 
Wrensch, 2006;(Health Promotion Administrtion, 2016). The glioma incidence rate is 
approximately 6 cases per 100,000 in the United States and 3 cases per 100,000 in Taiwan 
(Chien et al., 2016; Health Promotion Administrtion, 2016; Scarbrough, Akushevich, 
Wrensch, & Il'yasova, 2014). Although glioma is a rare malignancy, it is a highly fatal 
tumor, with the five year survival rate of 30% in the United States and 34.3% in Taiwan 
(Chien et al., 2016; Schwartzbaum et al., 2006).  
The etiology of glioma is largely unknown. Understanding glioma etiology can help 
develop prevention measures as well as to identify drug targets to improve treatment 
(Bondy et al., 2008). One way to explore a window of glioma susceptibility maybe via 
examining the associations between glioma and other diseases. Finding a connection 
between different diseases could help discovering the common etiological components. A 
suspected association between melanoma and glioma may help discover a common 
etiological component for the two malignancies and provide a new information guiding the 
development of new therapy. 
Several published reports support the familial association between glioma and 
melanoma, known as the melanoma-astrocytoma syndrome (Azizi et al., 1995; Kaufman, 
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Kimmel, Parisi, & Michels, 1993; Paunu et al., 2002; Scarbrough et al., 2014). At the 
population level, the association between melanoma and glioma was suggested by the 
analysis of the National Cancer Institute Surveillance Epidemiology and End Results 
(SEER) database in the United States (Scarbrough et al., 2014). This finding requires 
confirmation in other populations. Our hypothesis is that in Taiwan, melanoma patients 
have higher risk of glioma. To test this hypothesis, we used Taiwan National Health 
Insurance (NHI) research database.  
 
1.2 Research question and hypothesis  
Our research question is whether in the Taiwan Population ages 20 and over 
patients with melanoma have a greater risk of developing glioma as opposed to individuals 
without a melanoma history.  
Our hypothesis is that individuals with history of melanoma have a greater risk of 
developing glioma compared to those who do not have a history of melanoma.  
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CHAPTER II 
LITERATURE REVIEW  
2.1 Epidemiology of glioma 
Gliomas account for almost 80% of primary malignant brain tumors (Scarbrough 
et al., 2014; Schwartzbaum, Fisher, Aldape, & Wrensch, 2006). The world age-adjusted 
incidence rate was 3.7 cases per 100,000 for men and 2.6 cases per 100,000 for women 
(Bondy et al., 2008). In the United States, the age-adjusted incidence rates were 6 cases per 
100,000 and 3 cases per 100,000 in Taiwan (Bondy et al., 2008; Chien et al., 2016). 
Approximately 18,000 new diagnose cases and 13,000 deaths in the US(Schwartzbaum et 
al., 2006). The five year survival rate of 30% in the United States and 34.3% in Taiwan 
(Chien et al., 2016; Schwartzbaum et al., 2006). The incident rate changes in the different 
country. The glioma incident was higher in Europe, America, and Australia than in Asia 
and pacific area (Bondy et al., 2008; Schwartzbaum et al., 2006). Most malignant brain 
tumors have a greater incidence among males than in females (Bondy et al., 2008; Chien 
et al., 2016; Scarbrough et al., 2014). The incidence rate for glioma were 14.07 cases per 
100,000 person-years in adults and 0.18 cases per 100,000 person-years in children using 
data from United States, Belgium, and England (de Robles et al., 2015). The diagnosis 
tools and the level of medication might be the reason cause area difference between United 
States and Taiwan (Chien et al., 2016). The culture and the racism also need to take in to 
consider (Chien et al., 2016).  
The etiology of glioma remains mostly unknown. Several studies investigate the 
factors that might have the association with the glioma. Genetic predisposition to glioma 
is suggested by several syndromes, familial aggregation, linkage studies, and mutagen 
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sensitivity studies (Bondy et al., 2008). The only environmental factor linked to glioma 
risk is ionizing radiation (Bondy et al., 2008; Thompson et al., 1994). Specifically, 
therapeutic radiation has also been reported to be associated with glioma risk (Furst, 
Lundell, Holm, & Silfversward, 1988; Griem et al., 1994). The correlation between glioma 
and none ionizing radiation cell phone were also investigated but the results are mostly 
inconsistent (Bondy et al., 2008; Morgan, Miller, Sasco, & Davis, 2015). The atopic 
conditions, including allergies, and systemic infections have been reported to have inverse 
association with the glioma (Linos, Raine, Alonso, & Michaud, 2007). Other factors like 
viruses, neuro-carcinogens and metals are suspected to be associated with glioma (Bondy 
et al., 2008).  
 
2.2. Epidemiology of melanoma. 
Melanoma is the skin cancer that starts from the melanocytes cells. Although the 
occurrence of melanoma is less than non-melanoma, this malignancy presents the major 
cause of skin cancer mortality (WHO, 2016). Every year about 132,000 melanoma cases 
occur globally each year (WHO, 2016). The rates of melanoma have been increasing during 
the last 30 years. The rates of new melanoma cases is22 per  100,000 person-years in Unite 
States (WHO, 2016). In Taiwan, the age standardized incidence rate is 9.72 per 100,000 in 
males and 7.69 per 100,000 in females. The melanoma incidence rate are ranked as being 
the 8th most common malignancy among both males and females in 2013 in Taiwan and 
melanoma rates increase with age (Health Promotion Administrtion, 2016; NHIA, 2010). 
The risk factors of melanoma include both genetic and environmental factors. 
Among genetic factors, the nutation in CDKN2A have been associated with melanoma 
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(MacKie, Hauschild, & Eggermont, 2009). Males have higher rate than the female, 
probably due to hormonal differences (MacKie et al., 2009; Scarbrough et al., 2014). The 
ultraviolet radiation exposure, including artificial and natural, presents the major 
environmental risk factor for melanoma (Gefeller, Fiessler, Radespiel-Troger, Uter, & 
Pfahlberg, 2016; MacKie et al., 2009).  In addition, some case-control studies also showed 
that the pesticide exposure may contribute to the risk of melanoma (MacKie et al., 2009; 
Pukkala et al., 2002). 
 
2.3. Association between melanoma and glioma. 
Several published reports support the familial association between glioma and 
melanoma, known as the melanoma-astrocytoma syndrome (Azizi et al., 1995; Kaufman 
et al., 1993; Paunu et al., 2002; Scarbrough et al., 2014). At the population level, the 
association between melanoma and glioma was suggested by the analysis of the SEER 
database in the United States (Scarbrough et al., 2014). Although this association could be 
treatment-related, i.e. as reflecting increased risk of the second malignancy as a result of 
cancer therapy, the previous analysis of the SEER data did not confirm this hypothesis 
(Scarbrough et al., 2014). 
The common antigen expression and genetic alterations between melanoma and glioma 
have been supported by other studies studies (Killela et al., 2013; Kuan et al., 2011; 
Solomon et al., 2008). An inverse association atopic conditions with melanoma parallels 
similar inverse association between atopic conditions and glioma, suggesting a common 
genetic predisposition related to immunological factors (Linos et al., 2007).  
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CHAPTER III 
METHODOLOGY 
3.1 Data Source 
The nationwide population-based study was started in 1996. The data were obtained 
from the Taiwan National Health Insurance (NHI) research database which has been 
routinely collected by the National Health Research Institute (NHRI). Up to 99% of 23 
million Taiwanese population have been covered by the health insurance, making the 
insurance database an appropriate source of data for population-based studies. In this study, 
the data used represent a random sample of one million individuals from the NHI database 
for 1998 to 2010. The sample was selected by the NHRI from the total population, and the 
distribution of the sample was shown no difference compare with the total population.   
3.2 Definition of glioma and melanoma 
 Patients with glioma were identified using International Classification of Diseases, 
9th Revision, Clinical Modification (ICD-9-CM) code 191, 192.0-192.3, 192.8, 192.9, 225 
and 237.5. Melanoma was identified using ICD-9-CM code 172, 173, 190.0, 190.9, 192.1, 
216.X (X=0, 3-7, 9), 224, 223.2, 235.1, 235.2, 237.6, 238.2, 238.3, 238.8. Both conditions 
were identified in the claims database between 1 January 1998 and 31 December 2010. 
Patients less than age 20 were excluded from the database. 
3.3 Study variables 
Glioma identified by the selected ICD-9 code was our main outcome variable. Age, 
gender, and melanoma will be included in the data analysis as independent variables. Age 
was defined at baseline. For glioma patients, age at diagnosis was calculated from the initial 
day of registry in the database and specific age of diagnosing glioma or melanoma among 
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those who were 20 years of age or older. Age was also stratified by ten year interval, with 
the oldest age category being 80 years of age and older. 
3.4 Statistical analysis  
All statistical analyses were performed in SAS, version 9.2. Distribution of glioma 
and melanoma cases by age and gender were described. A Cox proportional hazard 
regression analysis was used to estimate the hazard ratios (HRs), and the accompanying 
95% confidence intervals (CIs) associated with each of the independent variable. HRs of 
glioma associated with melanoma were adjusted for age and gender. The value of P=0.05 
was considered significant.   
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CHAPTER IV 
RESULTS 
The current analysis included 675,121 patients after exclusion of those under 20 
years old. We identified 23,959 melanoma cases and 2219 glioma cases diagnosed between 
1998 and 2010. The follow-up time for each participant ranged from 0 to 13 person-years. 
Age distribution for melanoma and glioma cases are presented in Table 1. Table 1 
shows that the number of melanoma cases increases with age peaking at the fourth decade 
with slight decline at fifty and older (Table 1). And the number of glioma cases increased 
with age peaking at the fifth decade with slight decline at sixty and older (Table 1). The 
gender distribution showed that more females have melanoma (50.41%) and glioma 
(55.16%). Also, amongglioma patients with prior melanoma approximately 63% were 
females.  The risk of glioma adjusted for gender increased with age, with the the hazard 
ratio peaking at age group age from 60 to 69 and decrease after 70 years and older (Figure 
1). 
 The hazard ratio of developing glioma in melanoma patients was significantly 
higher among patients without melanoma (HR=6.18, 95%Cl=5.57-6.85), after adjusted 
gender and age (Table 2). The hazard ratio for developing glioma was lower for males, 
with the relative risk being 0.78 (95% CI = 0.714-0.844), after adjustment for age and 
history of melanoma (Table 2).  
   9 
Table 1. 
Age and gender distribution of glioma, melanoma, and glioma with prior melanoma 
cases. Cases were identified between 1998 and 2010. 
 Melanoma All gliomas All gliomas with prior melanoma 
Age    
 20-29 1685 (6.75%) 86 (3.88%) 6 (2.32%) 
 30-39 4999 (20.03%) 297 (13.38%) 29 (11.2%) 
 40-49 5941 (23.8%) 430 (19.38%) 46 (17.76%) 
 50-59 4984 (19.97%) 434 (19.56%) 51 (19.69%) 
 60-69 3318 (13.29%) 447 (20.14%) 47 (18.15%) 
 70-79 2795 (11.2%) 384 (17.31%) 59 (22.78%) 
 80+ 1237 (4.96%) 141 (6.35%) 21 (8.11%) 
 Total 24959 2219 259 
Gender    
 Male  12378 (49.59%) 995 (44.84%) 96 (37.07%) 
 Female 12581 (50.41%) 1224 (55.16%) 163 (62.93%) 
*For “Melanoma” and “glioma”, age category is determined by age at disease diagnosis. 
*For “prior melanoma”, age category is determined by age at all glioma diagnosis. 
 
Table 2. Association between history of melanoma and glioma risk 
 
 
  
Risk factor Hazard 
Ratio 
95% Confidence Limits 
History of melanoma 
(yes/no) 
6.39 5.77-7.08 
Gender (male vs. female) 0.78 0.71-0.84 
Age at baseline (years) 1.03 1.03-1.03 
Age at baseline (10 years) 1.34 1.31-1.37 
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Figure 1 
The hazard ratio of glioma in different age-groups as compare to age 20-29. The hazard 
ratio estimates were adjusted for the history of melanoma and gander. 
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CHAPTER V 
DISCUSSION AND CONCLUSION  
The main finding of this analysis is increased the hazard ratio of developing glioma 
in melanoma patients as compared to patients without melanoma history in this sample of 
the Taiwanese population: HR=6.18, 95%Cl=5.57-6.85 (Table 2). These results confirms 
the earlier finding in the US population (Scarbrough et al., 2014). Similarly to previously 
published studies, our analysis shows increasing risk of glioma up to age 70 (Scarbrough 
et al., 2014). However, unlike previous studies we found lower risk of glioma among males, 
whereas being a male has been an established demographic risk factor for glioma (Qi, Shao, 
Zhang, Hui, & Wang, 2013; Scarbrough et al., 2014). Also, lower proportion of males we 
found among melanoma patients, whereas previous studies consistently showed increased 
risk of melanoma among males (Qi et al., 2013; Scarbrough et al., 2014). It was suggested 
that males have a greater risk of glioma than females due to hormonal differences between 
genders (Qi et al., 2013; Scarbrough et al., 2014).  
The age distribution of both melanoma and glioma cases were as expected but the 
gender distributions of both malignancies were different from expected, i.e. females have 
the higher proportion than males. It is possible that although the selection of the study 
participants from the Taiwanese population was conducting using random procedure, the 
selected participants are different from the general population. Another explanation could 
be difference in risk factors for both malignancies in different populations. For example, 
ethnicity certainly differ between Taiwan and United States (Chien et al., 2016).  
The strength of our study is that the national insurance database was nation-wide 
all the participation were recorded their health condition every time they go to the hospital 
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and patient’s historical record (NHIA, 2010). The major limitation of this study is using a 
sample of the Taiwanese population as opposed to the entire population. Although the 
selection of the one million study participants was conducted using random sampling, this 
does not completely exclude selection bias.  
Overall, the data in the study show the relationship between melanoma and glioma. 
Our result provide direction for a future study in glioma analysis in the total Taiwan 
population and eastern population.  
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